Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
News|Slideshows|May 14, 2020
COVID-19 Consequences: Takeaways from a Mental Health Survey of US Adults
Author(s)Sydney Jennings
Over half of US adults who responded to a new survey said COVID-19 has impacted their mental health. To what extent? Find out in our new slideshow.
Advertisement
In honor of May being National Mental Health Awareness Month,
Advertisement
Related to this article
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
Hormone Therapy Linked to More Frequent Migraines, but Not Greater Severity, in Postmenopausal Women
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Advertisement
Advertisement
Trending on Patient Care Online
1
American Cancer Society Updates Prostate Cancer Screening Guidelines
2
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
3
Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial
4
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
5